Contribute Try STAT+ Today

ATLANTA — The remarkable ability of CAR-T therapies to eradicate cancer cells from desperately ill patients does not come without serious safety risks, notably the inflammatory storm called cytokine release syndrome and neurological side effects, including confusion and swelling of the brain. Currently, CAR-T therapy is administered in the hospital so admitted patients can be monitored closely for any warning signs. This adds costs to the already expensive treatment.

It also raises a key question: As CAR-T therapy evolves, will it ever become safe enough so patients can be treated and cared for outside the hospital?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.